Xeltis is among seven European companies selected to join the prestigious research network ArtMoMa. The program aims to reach new heights in the emerging field of artificial molecular machines, including supramolecular technology. ArtMoMa is built [...]

Deutsche -  Xeltis has been selected with three other Swiss companies to illustrate how medtech innovation can pave new ways to improve patients’ lives at the Spirit of Bern conference on 27th February. The [...]

For more on the data, please click here CEO announced continuation of the clinical trial program for the pulmonary valve in EU, Asia and USA Clinical trial results of Xeltis pulmonary valve (PV) show promising [...]

Xeltis closed a €10.5 million Series D financing round to support its vascular and valve trial programs this week. The funding was provided by existing institutional and private investors, including all venture capital funds [...]

Positive preclinical results from the three different applications of Xeltis’ restorative small diameter blood vessels have been presented at 2019 International Symposium for Applied Cardiovascular Biology and Vascular Tissue Engineering in Zurich (CH). All [...]

Preclinical data on Xeltis’ restorative heart valves will illustrate supramolecular materials’ potential application in clinical practice at the Society for Biomaterials annual meeting on Thursday 4 April. Xeltis CTO Martijn Cox will present 2-year [...]

A cardiovascular strategy to best leverage the potential of its RestoreX™ technology platform has been shared by Xeltis CEO Eliane Schutte at Biocapital Europe meeting in Amsterdam today. The company is moving forward with [...]

Peer-reviewed journal Cardiovascular Pathology published positive one-year in-vivo data on Xeltis’ RestoreX™ technology platform in its latest issue. According to the paper, preclinical results of RestoreX™ pulmonary graft confirmed the potential of Xeltis’ restorative cardiovascular [...]